All In Biotech

Drug Trial Radar · NCT04082364

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Last checked: Nov 20, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

82

Actual

Start

Sep 30, 2019

Primary completion

Jan 15, 2024

Study completion Mar 25, 2025

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
Collaborators
Zai Lab (Shanghai) Co., Ltd.
First posted
Sep 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts. Part A is a single-arm cohort (Cohort A, 40 to 110 participants) will evaluate safety and efficacy of margetuximab plus retifanlimab. Part B Part 1 has 4 arms (50 patients/arm). Participants will be randomized to margetuximab plus retifanlimab plus chemotherapy, margetuximab plus tebotelimab, plus chemotherapy, margetuximab plus chemotherapy, or trastuzumab plus chemotherapy.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • HER2-positive Gastric Cancer

Interventions

  • margetuximabBiological

    margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle

  • RetifanlimabBiological

    Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.

  • TebotelimabBiological

    Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.

  • TrastuzumabBiological

    Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle

  • ChemotherapyOther

    Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6 Chemotherapy XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0Time frame: Throughout the study, an average of 11 months.
  2. Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology ReviewsTime frame: Throughout the study, an average of 11 months.

Locations

73 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale

    Scottsdale, Arizona

  • City of Hope Comprehensive Cancer Center - Duarte

    Duarte, California

  • Norris Comprehensive Cancer Center (USC)

    Los Angeles, California

  • Salinas Memorial

    Salinas, California

  • UCLA School of Medicine

    Santa Monica, California

  • Yale University

    New Haven, Connecticut

  • Florida Cancer Specialists South

    Fort Myers, Florida

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala

    Ocala, Florida

  • Florida Cancer Specialists North

    St. Petersburg, Florida

  • Kaiser Permanente

    Honolulu, Hawaii

  • University of Chicago

    Chicago, Illinois

  • Edward H. Kaplan MD & Associates

    Skokie, Illinois

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion

    Grand Rapids, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Heme Onc

    Lincoln, Nebraska

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • The University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Stephenson Cancer Center at OUHSC

    Oklahoma City, Oklahoma

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Oncology Consultants

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Swedish Cancer Institute

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Beijing Cancer Hospital

    Beijing, China

  • Jilin Cancer Hospital (Second People's Hospital Of Jilin Province)

    Changchun, China

  • Fujian Medical University - Fujian Provincial Cancer Hospital (Fujian Provincial Tumor Hospital)

    Fuzhou, China

  • SIR RUN RUN SHAW Hospital, Zhejiang University school of medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Affiliated Tumor Hospital of Harbin Medical University- the 3rd Affiliated Hospital of Harbin

    Harbin, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Anhui Provincial Cancer Hospital

    Hefei, China

  • Jinan Center Hospital

    Jinan, China

  • Nanjing University Medical School; Nanjing Drug Tower

    Nanjing, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Liaoning cancer hospital

    Shenyang, China

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.